We can’t ignore what AI makes possible: faster diagnoses, smarter workflows, better use of limited resources, and more personalized care at scale. If we get this right, we can build a system that works better for everyone, not just the few who can afford concierge care or live near major medical centers.
We're getting close to the July 19 deadline for submissions. Don't miss this opportunity to pitch your company to a team of investors at INVEST Digital Health in Dallas on September 18!
Break down the silos. Take control of your provider data.
Instead of an engineered peptide to activate gut receptors to trigger metabolic effects, Syntis’s technology forms a coating in intestines that has the effect of redirecting nutrients, mimicking an effect of gastric bypass surgery. In other obesity medicine news, Protagonist Therapeutics revealed a drug candidate that puts it in competition with Novo Nordisk and Eli Lilly, among others.
The conference will explore ethical considerations for AI in healthcare, how the healthcare industry is managing the teething challenges of AI "hallucinations", practical concerns such as efficacy and ROI, and more. Register today!
Draig Therapeutics’ lead drug is designed to safely target the AMPA receptor as a way of mediating the interplay between two neurotransmitters whose imbalance is associated with mood disorders. The startup is one of several that have recently raised mega rounds of financing to support programs in the clinic or entering clinical testing.
The healthcare startup pitch contest will be the centerpiece of INVEST Digital Health in Dallas on September 18. Apply today!
The home care industry is booming. As Baby Boomers age and more families seek in-home solutions for loved ones, demand for home care services is at an all-time high.
The future of digital behavioral health won’t be found in yet another standalone app or fragmented series of platforms. It will be built by re-centering care around clinicians empowered by digital technology.
Robotics has already revolutionized fields like orthopedics and laparoscopic surgery. Endovascular care deserves the same leap forward. The technology exists. The evidence is strong. The challenge now is adoption.
Antares Therapeutics spun off of Scorpion Therapeutics, a clinical-stage biotech that Eli Lilly acquired earlier this year. Like Scorpion, Antares is developing small molecules that go after undruggable targets in cancer.
Business banking provider* Mercury sponsored a webinar discussing early stage investment topics with venture capitalists such as grant funding secrets, capital valuation, the role of AI in life sciences, and more.
A new report by Paubox calls for healthcare IT leaders to dispose of outdated assumptions about email security and address the challenges of evolving cybersecurity threats.
MedCity INVEST Digital Health on September 18 at Pegasus Park in Dallas will explore AI through a series of discussions leading up to our annual Pitch Perfect contest, where healthcare startups pitch their companies to a team of investor judges. Register today!
Eli Lilly’s acquisition of SiteOne Therapeutics comes ahead of Phase 2 testing of the startup’s lead drug candidate, which blocks the NaV1.8 sodium channel to treat pain. This target has clinical and regulatory validation from the recent FDA approval of Vertex Pharmaceuticals’ pain drug, Journavx.
Startup finalists competed in four tracks: biopharma; devices and diagnostics; health tech aimed at consumers and self-insured employers; and health tech aimed at payers and providers. Investor judges in each track selected the winners.
The law that created ASTP as a formal federal agency gave it duties such as supporting a more effective marketplace and greater competition. Stephen Konya, ASTP’s chief, innovation and strategic partnerships, explained how the agency carries out its mission.
In a webinar sponsored by fintech business Mercury, investors from Breyer Capital and MBX Capital shared their startup trend perspectives on AI, valuation, and alternative funding.